Bayer Net Profit Falls on Lower Sales, Currency Headwinds
By Helena Smolak
Bayer posted a fall in first-quarter net profit on declining sales across all segments as well as currency headwinds.
The German pharmaceutical and agricultural company said Tuesday that net profit was 2 billion euros ($2.16 billion), down from EUR2.18 billion the previous year but above analysts' forecasts of EUR1.73 billion, according to a Vara Research consensus.
Earnings before interest, taxes, depreciation, amortization and special items declined to EUR4.41 billion from EUR4.47 billion while earnings before interest and taxes rose to EUR3.09 billion from EUR2.97 billion, Bayer said.
Sales declined 4.3% to EUR13.77 billion due to less demand across its pharmaceuticals, consumer health and crop science segments, missing a consensus forecast of EUR14.08 billion.
The company said sales at its agricultural business, crop science, fell 3% on an adjusted basis to EUR7.91 billion due to lower volumes for non-glyphosate-based herbicides and its fungicides business in Europe, Middle East and Africa. On an adjusted basis, sales at its pharmaceuticals division rose 3.9% to EUR4.36 billion, boosted by higher sales of its new cancer drug Nubeqa and its kidney disease treatment Kerendia, Bayer said.
The company backed its currency-adjusted 2024 guidance.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
May 14, 2024 02:13 ET (06:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations